Eli Lilly stock climbs on Ventyx buyout talk as dealmaking takes center stage
Eli Lilly shares rose 3.3% to $1,099.44 after reports it is in advanced talks to buy Ventyx Biosciences for over $1 billion, according to the Wall Street Journal. The news follows Lilly’s new obesity-drug partnership with Nimbus and comes as Novo Nordisk launches an oral Wegovy pill in the U.S. Investors await updates at next week’s J.P. Morgan healthcare conference and Lilly’s upcoming earnings call.